NYSE:ARMP

Armata Pharmaceuticals Stock Insider Trading

etoro logo Buy ARMP
*Your capital is at risk
$7.08
+0.0200 (+0.283%)
At Close: Jun 18, 2026

Armata Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 97.80. In total, the insiders bought 5.12M and sold 93.25K ARMP shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
97.80
Buy 5.12M shares
Sell 93.25K shares
90% Buy Activity
Weak Positive Correlation
Buy Signal High Confidence
Mar 09, 2026

Analysis Breakdown:

  • Strongly supported by a very high Insider Power Score of 97.8.
  • Confidence increased due to high data reliability score of 90.
  • Supported by overwhelming buy-side pressure (90% buys).

Historical Insider Trades

Date Type Person Role Amount
Apr 24, 2026
Buy
Stock Options (Right to Buy)
A-Award
Gilmer Daniel B.
Director
Director 51 280
Value: $662.5K
Apr 24, 2026
Buy
Common Stock
J-Other
Gilmer Daniel B.
Director 0
Value: $0
Mar 14, 2026
Sell
Common Stock
F-InKind
Kyme Pierre
Chief Business Officer
Officer 1 030
Value: $10.9K
Mar 14, 2026
Sell
Common Stock
F-InKind
Birx Deborah
Chief Executive Officer
CEO / President 4 919
Value: $51.8K
Mar 09, 2026
Buy
Stock Options (Right to Buy)
A-Award
Birx Deborah
Chief Executive Officer
CEO / President 421 226
Value: $4.89M
Mar 09, 2026
Buy
Stock Options (Right to Buy)
A-Award
Peterson Todd C.
Director
Director 25 640
Value: $297.7K
Mar 09, 2026
Buy
Stock Options (Right to Buy)
A-Award
House David Duane
SVP, Finance, And Pfo
Officer 109 885
Value: $1.28M
Mar 09, 2026
Buy
Stock Options (Right to Buy)
A-Award
Kramer Robin
Director
Director 25 640
Value: $297.7K
Mar 09, 2026
Buy
Stock Options (Right to Buy)
A-Award
Kyme Pierre
Chief Business Officer
Officer 183 142
Value: $2.13M
Mar 09, 2026
Buy
Stock Options (Right to Buy)
A-Award
Patti Joseph M
Director
Director 25 640
Value: $297.7K
Mar 09, 2026
Buy
Stock Options (Right to Buy)
A-Award
Odysseas Kostas D
Director
Director 25 640
Value: $297.7K
Mar 09, 2026
Buy
Stock Options (Right to Buy)
A-Award
Schlesinger Sarah J.
Director
Director 25 640
Value: $297.7K
Mar 09, 2026
Buy
Stock Options (Right to Buy)
A-Award
Haimovitz Jules
Director
Director 25 640
Value: $297.7K
Jul 10, 2025
Sell
Common Stock
F-InKind
Birx Deborah
Chief Executive Officer
CEO / President 13 637
Value: $31.0K
Jul 10, 2025
Sell
Common Stock
F-InKind
Birx Deborah
Chief Executive Officer
CEO / President 13 637
Value: $31.0K
Mar 14, 2025
Sell
Common Stock
F-InKind
Birx Deborah
Chief Executive Officer
CEO / President 6 061
Value: $11.8K
Mar 14, 2025
Sell
Common Stock
F-InKind
Kyme Pierre
Chief Business Officer
Officer 1 027
Value: $2K
Mar 14, 2025
Sell
Common Stock
F-InKind
Kyme Pierre
Chief Business Officer
Officer 1 027
Value: $2K
Mar 14, 2025
Sell
Common Stock
F-InKind
Birx Deborah
Chief Executive Officer
CEO / President 6 061
Value: $11.8K
Feb 05, 2025
Buy
Stock Options (Right to Buy)
A-Award
Odysseas Kostas D
Director
Director 54 343
Value: $110.9K
Feb 05, 2025
Buy
Stock Options (Right to Buy)
A-Award
Schlesinger Sarah J.
Director
Director 54 343
Value: $110.9K
Feb 05, 2025
Buy
Stock Options (Right to Buy)
A-Award
Peterson Todd C.
Director
Director 54 343
Value: $110.9K
Feb 05, 2025
Buy
Stock Options (Right to Buy)
A-Award
Patti Joseph M
Director
Director 54 343
Value: $110.9K
Feb 05, 2025
Buy
Stock Options (Right to Buy)
A-Award
Kyme Pierre
Chief Business Officer
Officer 100 000
Value: $204.0K
Feb 05, 2025
Buy
Stock Options (Right to Buy)
A-Award
Kramer Robin
Director
Director 54 343
Value: $110.9K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT ARMATA PHARMACEUTICALS INC.
Armata Pharmaceuticals
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It h...
GOLDEN STAR
Ticker Change Signal Date
IDYA
$28.98
7.76% Jun 12
DHI
$146.71
7.57% Jun 10
PHM
$118.49
7.15% Jun 10
EAT
$140.46
17.39% Jun 05
TPR
$140.47
2.16% Jun 04

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE